Free Trial
NASDAQ:AURA

Aura Biosciences Q2 2025 Earnings Report

Aura Biosciences logo
$6.46 +0.05 (+0.70%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aura Biosciences EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Aura Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aura Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Aura Biosciences' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aura Biosciences Earnings Headlines

What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
Aura Biosciences Posts Q2 Cash Surge
See More Aura Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email.

About Aura Biosciences

Aura Biosciences (NASDAQ:AURA) is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer. AU-011 consists of a VLP conjugated to a photoactivatable dye, which binds preferentially to tumor cells in the eye. Once bound, the treatment is activated by a noninvasive near-infrared laser, triggering a localized photochemical reaction that selectively kills cancer cells. Early‐stage clinical trials have demonstrated encouraging safety and tumor control signals, supporting ongoing pivotal development.

In addition to its ophthalmic program, Aura Biosciences is advancing research in head and neck cancers and other solid tumor indications. The company is collaborating with leading academic centers and research institutions to explore combination regimens and to expand the therapeutic potential of its VLP platform. Aura’s development strategy includes both monotherapy and combination approaches, with plans to initiate additional clinical studies in the coming years.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Aura Biosciences has built a leadership team with extensive experience in oncology drug development and photodynamic therapy. The company maintains operations in North America and Europe, and it listed its common shares on the Nasdaq Global Market under the ticker symbol AURA. With a growing pipeline and a differentiated technology platform, Aura is positioned to address significant unmet needs in the treatment of solid tumors through targeted, light-activated therapeutics.

View Aura Biosciences Profile

More Earnings Resources from MarketBeat